Exemestane (Aromasin) can be used alone
From MedScape, this is a report of the TEAM study that looked at the use of exemestane (aromasine) alone for five years vs. two or three years of tamoxifen followed by aromasine. Both groups of women did equally well. This is another step in the ongoing study of the bet use of hormonal therapies for women with ER positive breast cancers. There is still variation among doctors re how to use these medications, and only slowly are we learning the best strategies.
Here is an excerpt and then a link to read more:
January 18, 2011 — Exemestane used alone for 5 years is similar to exemestane used after 2 to 3 years of tamoxifen in the prevention of relapse in postmenopausal women with hormone-responsive early breast cancer. This is the conclusion from the huge Tamoxifen Exemestane Adjuvant Multinational (TEAM) study, published online today in the Lancet.
The TEAM results have already been presented at major meetings, and have been discussed in some detail, as previously reported byMedscape Medical News.
Currently, exemestane is approved for use only after 2 to 3 years of tamoxifen.
The results from the TEAM study show that exemestane can either follow tamoxifen or be used alone for 5 years and achieve similar outcomes.